DAVID SCHNELL, MD
David is as a Managing Director and co-founded Prospect Ventures in 1997. Prospect has raised more than $1B in committed capital through three funds dedicated to investing in and supporting breakthrough biomedical companies. David has led a large number of successful investments for Prospect Ventures in biotechnology including serving on the Board of Directors of Gloucester Pharmaceuticals, Kythera Biopharmaceuticals, NGM Biopharmaceuticals, Rinat Neurosciences, Senomyx, Trubion and Amira among others.
Prior to Prospect Ventures, David was a Partner at Kleiner Perkins Caufield & Byers (KPCB). At KPCB, David led a series of successful investments in early stage biotechnology companies. He also co-founded and served as CEO of the pioneering health care information company Healtheon Corporation. Healtheon subsequently went public and merged with WebMD in a deal worth $6 billion.
Previously, David spent seven years at Sandoz Pharmaceuticals (presently Novartis) where he held a number of executive management positions. While at Sandoz, David's responsibilities included strategic operations, product marketing, and business development in the US and Switzerland. David received his MD degree from Harvard Medical School and MA and BS from Stanford University.
Harvard Medical School – MD
Stanford School of Medicine – MA
Stanford University – BS
David Schnell online:
Bloomberg’s Executive Profile of Prospect Ventures David Schnell
Bloomberg’s People Profile of Prospect Ventures David Schnell
Prospect Ventures David Schnell on Crunchbase
Prospect Ventures David Schnell on NGM Biopharmaceuticals
Prospect Ventures David Schnell on Innovator’s Edge
Prospect Ventures David Schnell on Equilar
Prospect Ventures David Schnell on Relationship Science